Clinical cancer research : an official journal of the American Association for Cancer Research

Clin Cancer Res · ISSN (e) 1557-3265 · 13 papers in corpus
other 2024
doi:10.1158/1078-0432.CCR-23-2819 ·PMID:38687597

PURPOSE: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. EXPERIMENTAL DESIGN: Gynecologic cancers with available somatic molecular …

review 2024
doi:10.1158/1078-0432.CCR-24-1205 ·PMID:39141515

Clear-cell carcinomas (CCC) arising from the gynecologic tract (including from the ovary, endometrium, cervix, vulva, or vagina) represent rare but clinically significant entities with intriguing overlapping characteristics. Epidemiological…

other 2022
doi:10.1158/1078-0432.CCR-21-3817 ·PMID:35816189

PURPOSE: To identify molecular subclasses of clear cell ovarian carcinoma (CCOC) and assess their impact on clinical presentation and outcomes. EXPERIMENTAL DESIGN: We profiled 421 primary CCOCs that passed quality control using a targeted…

article 2014
doi:10.1158/1078-0432.ccr-14-1338 ·PMID:25294912

PURPOSE: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian tumors p…

article 2013
doi:10.1158/1078-0432.ovca13-b71

Abstract Introduction: Endometriosis is a largely benign, chronic inflammatory disease defined by the presence of endometrial-like glands surrounded by stroma. Epidemiologic studies suggest that endometriosis is an independent risk factor f…

article 2013
doi:10.1158/1078-0432.ccr-12-2726 ·PMID:23362326

PURPOSE: Endometriosis, a largely benign, chronic inflammatory disease, is an independent risk factor for endometrioid and clear cell epithelial ovarian tumors. We aimed to identify plasma miRNAs that can be used to differentiate patients w…

letter 2013
doi:10.1158/1078-0432.ccr-13-0561 ·PMID:23616637

In a recent article, Suryawanshi and colleagues reported that alterations of plasma microRNAs (miRNA or miR) may be novel biomarkers for endometriosis and endometriosis-associated ovarian cancer (1). However, we have some concerns about the…

letter 2013
doi:10.1158/1078-0432.ccr-13-1022 ·PMID:23616635

We are pleased that our research (1) has generated interest in the scientific community, and we are happy to provide our reply to the comments submitted by Dr. Haifeng Qiu.The major concern addressed by Dr. Qiu is that the upregulation of p…

other 2011
doi:10.1158/1078-0432.CCR-11-1388 ·PMID:21903772

PURPOSE: Genetically engineered mouse (GEM) models of ovarian cancer that closely recapitulate their human tumor counterparts may be invaluable tools for preclinical testing of novel therapeutics. We studied murine ovarian endometrioid aden…

article 2008
doi:10.1158/1078-0432.ccr-07-1614 ·PMID:18172249

PURPOSE: Endometriotic cysts are known to transform into ovarian cancers, such as clear cell and endometrioid carcinomas. We hypothesized that an iron-rich environment produced by the repetition of hemorrhage in the endometriotic cysts duri…

article 2003
·PMID:14613992

PURPOSE: It has been hypothesized that circulating androgens may be involved in the development of ovarian cancer. The androgenic medication, danazol, and the antiandrogenic medications, leuprolide and nafarelin, are commonly used in the tr…

other 2002
·PMID:12060613

PURPOSE: The purpose of this study was to examine ovarian cancer cells for the expression of decorin, a proteoglycan component of the cell matrix that can inhibit cancer cell growth. EXPERIMENTAL DESIGN: Cultured ovarian cancer cells and s…

other 2000
·PMID:10690545

The DNA base excision repair pathway is responsible for the repair of alkylation and oxidative DNA damage. A crucial step in the base excision repair pathway involves the cleavage of an apurinic/apyrimidinic (AP) site in DNA by an AP endonu…